Abstract
NSCLC is associated with an increasing number of molecularly defined subsets, several of which now have approved targeted therapies. Variation in how different biomarker assays are utilised is likely. We sought to determine the current biomarker testing practices from the perspective of medical oncologists (MO) and pathologists (P) at Australian sites to understand variations in practice and potential influencing factors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
